RxDoctor Payments Data

Jose Acuna, MD

Internal Medicine · Lakeland, FLNPI 1780879163

Payments from drug & device makers

$830in general payments, 2019–2025

Across 18 payments — averaging $46.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$305
  • Cvrx, Inc.$168
  • Novo Nordisk$143
  • Bayer$44
  • Pfizer$28
  • Almatica Pharma LLC$24
  • plus $117 from 6 others

What the payments were for

  • Food & beverage$830100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$830 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$21,193
Medicare patients
82
Services billed
396

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide123$157,423
OzempicSemaglutide140$152,736
MounjaroTirzepatide89$110,608
EliquisApixaban103$97,915
JardianceEmpagliflozin70$61,187
JanuviaSitagliptin Phosphate33$33,099
FarxigaDapagliflozin Propanediol27$30,880
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$26,314
XareltoRivaroxaban35$25,610
Tresiba Flextouch U-100Insulin Degludec34$22,434
EntrestoSacubitril/Valsartan25$22,419
Combivent RespimatIpratropium/Albuterol Sulfate40$21,229
Breo ElliptaFluticasone/Vilanterol33$13,104
TradjentaLinagliptin11$12,679
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$12,198

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$305$268,031212 claims
Novo NordiskOzempic$143$152,736140 claims
Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta, Spiriva Respimat$24$106,905143 claims
PfizerEliquis$28$97,915103 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$12$49,69470 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Lakeland

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →